The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor pathway inhibitor.

Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...

Basel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Pluvicto (lutetium Lu 177 ...

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with ...

Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...

The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane ...

In the study, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) reduced the risk of radiographic progression or death by 59% ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

NEW YORK – The US Food and Drug Administration on Friday expanded the indication for Novartis' radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for use prior to chemotherapy in ...

The news from Buckingham palace was shocking. Over a year after King Charles had announced that he had been diagnosed with ...

As King Charles continues to undergo treatment for his cancer, HELLO! has everything you need to know about the royal's ...

Diagnosed with aggressive prostate cancer, 62-year-old Alistair Knott is defying his prognosis by taking on the ultimate test ...